巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-10-25
2023-06-30
2021-09-11
2023-02-22
2023-06-12
2021-12-22
2023-12-05
2023-04-06
2023-03-04
2021-09-07
2021-12-15
